[go: up one dir, main page]

PE20080951A1 - DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS - Google Patents

DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Info

Publication number
PE20080951A1
PE20080951A1 PE2007000978A PE2007000978A PE20080951A1 PE 20080951 A1 PE20080951 A1 PE 20080951A1 PE 2007000978 A PE2007000978 A PE 2007000978A PE 2007000978 A PE2007000978 A PE 2007000978A PE 20080951 A1 PE20080951 A1 PE 20080951A1
Authority
PE
Peru
Prior art keywords
protein
substituted
propionamide
ethyl
amino
Prior art date
Application number
PE2007000978A
Other languages
English (en)
Inventor
Mark G Charest
Christine Hiu-Tung Chen
Zhuoliang Chen
Miao Dai
Feng He
Huangshu Lei
Ly Luu Pham
Sushil Kumar Sharma
Christopher Sean Straub
Run-Ming David Wang
Fan Yang
Leigh Zawel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080951(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080951A1 publication Critical patent/PE20080951A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS DE FORMULA (I), EN DONDE R1 ES H, ALQUILO(C1-C4), ALQUENILO(C2-C4), ENTRE OTROS; R2 ES H, ALQUILO(C1-C4), ALQUENILO(C2-C4),ENTRE OTROS; R3 ES H, CF3, C2F5, ENTRE OTROS; R4 ES ALQUILO(C0-C10), ALQUENILO(C0-C10), ENTRE OTROS; A ES HETEROCICLICO SUSTITUIDO O NO SUSTITUIDO; D ES ALQUILENO(C1-C7), C(O), O, ENTRE OTROS; A1 ES ARILO, HETEROCICLICO, SUSTITUIDOS O NO SUSTITUIDOS; Q ES H, ALQUILO(C1-C10), ALCOXILO(C1-C10), ENTRE OTROS; n ES DE 0 A 7. SON PREFERIDOS: (S)-N-((S)-1-CICLOHEXIL-2-{(S)-2-[4-(4-FLUORO-BENZOIL)-TIAZOL-2-IL]-PIRROLIDIN-1-IL}-2-OXO-ETIL)-2-METIL-AMINO-PROPIONAMIDA; (S)-N-[(S)-CICLOHEXIL-(ETIL-{(S)-1-[5-(4-FLUORO-BENZOIL)-PIRIDIN-3-IL]-PROPIL}-CARBAMOIL)-METIL]-2-METIL-AMINO-PROPIONAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS(IAP) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS, INCLUYENDO CANCER
PE2007000978A 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS PE20080951A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83500006P 2006-08-02 2006-08-02

Publications (1)

Publication Number Publication Date
PE20080951A1 true PE20080951A1 (es) 2008-09-11

Family

ID=38686647

Family Applications (5)

Application Number Title Priority Date Filing Date
PE2011000113A PE20110220A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000111A PE20110217A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000112A PE20110218A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000114A PE20110224A1 (es) 2006-08-02 2007-07-26 PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
PE2007000978A PE20080951A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PE2011000113A PE20110220A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000111A PE20110217A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000112A PE20110218A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000114A PE20110224A1 (es) 2006-08-02 2007-07-26 PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO

Country Status (41)

Country Link
US (3) US8552003B2 (es)
EP (3) EP2051990B1 (es)
JP (1) JP4875749B2 (es)
KR (2) KR101087878B1 (es)
CN (2) CN101511860B (es)
AR (3) AR062159A1 (es)
AU (1) AU2007281230B2 (es)
BR (1) BRPI0714803B8 (es)
CA (1) CA2658525C (es)
CL (1) CL2007002234A1 (es)
CR (2) CR10567A (es)
CU (2) CU23866B1 (es)
DK (1) DK2051990T3 (es)
DO (1) DOP2013000084A (es)
EA (2) EA201401247A1 (es)
ES (2) ES2559042T3 (es)
GE (1) GEP20115251B (es)
GT (2) GT200900019A (es)
HN (1) HN2009000214A (es)
HR (1) HRP20130373T1 (es)
IL (3) IL196596A (es)
JO (1) JO2848B1 (es)
MA (1) MA30652B1 (es)
ME (1) ME00585B (es)
MX (1) MX2009001212A (es)
MY (1) MY150460A (es)
NI (2) NI200900008A (es)
NO (1) NO342230B1 (es)
NZ (1) NZ574393A (es)
PA (1) PA8740901A1 (es)
PE (5) PE20110220A1 (es)
PL (1) PL2051990T3 (es)
PT (1) PT2051990E (es)
SI (1) SI2051990T1 (es)
SM (1) SMP200900013B (es)
SV (1) SV2009003160A (es)
TN (1) TN2009000034A1 (es)
TW (1) TWI408133B (es)
UA (1) UA95485C2 (es)
WO (1) WO2008016893A1 (es)
ZA (1) ZA200900371B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080242658A1 (en) 2004-04-07 2008-10-02 Mark G Palermo Inhibitors of Iap
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
EP1836201B2 (en) 2004-12-20 2013-09-04 Genentech, Inc. Pyrrolidine inhibitors of iap
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
JP2009512719A (ja) 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Ｉａｐｂｉｒドメイン結合化合物
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
SG171682A1 (en) 2006-05-16 2011-06-29 Aegera Therapeutics Inc Iap bir domain binding compounds
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
AR063943A1 (es) 2006-07-24 2009-03-04 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer.
CL2007002166A1 (es) 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
US20100316573A1 (en) * 2006-10-19 2010-12-16 Larry Alexander Gaither Organic Compounds
US8492429B2 (en) * 2006-11-28 2013-07-23 Novartis Ag Combination of IAP inhibitors and FLT3 inhibitors
EA200900691A1 (ru) * 2006-11-28 2009-12-30 Новартис Аг Применение ингибиторов iap для лечения острого миелоидного лейкоза
JP2010513561A (ja) * 2006-12-19 2010-04-30 ジェネンテック， インコーポレイテッド Ｉａｐのイミダゾピリジンインヒビター
CA2683392A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
WO2009140447A1 (en) * 2008-05-16 2009-11-19 Novartis Ag Immunomodulation by iap inhibitors
EP2318395A4 (en) 2008-08-02 2011-10-26 Genentech Inc IPA INHIBITORS
US8841067B2 (en) 2009-01-09 2014-09-23 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
TW201109335A (en) 2009-08-04 2011-03-16 Takeda Pharmaceutical Heterocyclic compounds
WO2011019782A1 (en) * 2009-08-11 2011-02-17 Novartis Ag Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
BR112012003118A2 (pt) * 2009-08-12 2016-02-23 Novartis Ag formulações orais sólidas e formas cristalinas de um inibidor de proteína apoptose
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
KR101560227B1 (ko) * 2010-08-31 2015-10-14 한미사이언스 주식회사 세포사멸 유도 활성을 갖는 퀴놀린 또는 퀴나졸린 유도체
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
EP2731942B1 (en) 2011-07-13 2015-09-23 Novartis AG Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
US20140243276A1 (en) 2011-09-30 2014-08-28 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
JP6267193B2 (ja) * 2012-05-22 2018-01-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換ジピリジルアミン類及びそれらの使用
KR20140011773A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 이중 저해 활성을 갖는 헤테로고리 유도체
CA2907912A1 (en) 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
KR20200108904A (ko) 2013-06-25 2020-09-21 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR20220126813A (ko) 2014-03-14 2022-09-16 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
AR103894A1 (es) 2015-03-10 2017-06-14 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del estimulador del gen interferón
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EA201891093A1 (ru) 2015-11-03 2018-10-31 Янссен Байотек, Инк. Антитела, специфически связывающие pd-1, и их применение
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
US10781205B2 (en) 2016-04-20 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106496213B (zh) * 2016-09-30 2019-08-20 东南大学 Lcl161前药及其制备方法和应用
JP6899993B2 (ja) * 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 複素環化合物
BR112019016737A2 (pt) 2017-03-31 2020-03-31 Boehringer Ingelheim International Gmbh Terapia anticâncer combinada
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
JP7515175B2 (ja) 2018-07-31 2024-07-12 ファイメクス株式会社 複素環化合物
JP7504106B2 (ja) 2019-01-17 2024-06-21 デビオファーム・インターナショナル・エス・アー がんの処置のための組合せ物
TWI894135B (zh) 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
AU2020256220A1 (en) 2019-04-04 2021-09-16 Dana-Farber Cancer Institute, Inc. CDK2/5 degraders and uses thereof
WO2020236825A2 (en) 2019-05-20 2020-11-26 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2021020585A1 (ja) 2019-07-31 2021-02-04 ファイメクス株式会社 複素環化合物
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
PH12022550721A1 (en) 2019-09-25 2024-05-13 Debiopharm Int Sa Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US12171795B2 (en) 2020-06-03 2024-12-24 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein
CA3202759A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022112942A2 (en) 2020-11-24 2022-06-02 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
KR20250027281A (ko) 2022-05-20 2025-02-25 노파르티스 아게 Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
JPS59141547A (ja) 1983-02-01 1984-08-14 Eisai Co Ltd 鎮痛作用を有する新規ペプタイドおよび製法
FR2575753B1 (fr) 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5559209A (en) 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6472172B1 (en) 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
AU2001265008A1 (en) 2000-05-23 2001-12-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US20020160975A1 (en) 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
US20030157522A1 (en) 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
JP4541882B2 (ja) 2002-07-02 2010-09-08 ノバルティス アーゲー Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤
DE60324964D1 (de) 2002-07-15 2009-01-08 Univ Princeton Iap-bindende verbindungen
US20040171554A1 (en) 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
WO2005049853A2 (en) 2003-11-13 2005-06-02 Genentech, Inc. Compositions and methods for screening pro-apoptotic compounds
CA2553871A1 (en) * 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
SE527038C2 (sv) * 2004-02-26 2005-12-13 Ingenjoers N Per Oskar Persson Kassett och apparat för vätskefrysning
WO2005084317A2 (en) 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
US20080242658A1 (en) 2004-04-07 2008-10-02 Mark G Palermo Inhibitors of Iap
EP1778718B1 (en) 2004-07-02 2014-10-08 Genentech, Inc. Inhibitors of iap
EP1836201B2 (en) 2004-12-20 2013-09-04 Genentech, Inc. Pyrrolidine inhibitors of iap
US20060218632A1 (en) * 2005-03-28 2006-09-28 Cisco Technology, Inc.; Method and system for installing premise equipment
AU2007307763A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
RU2009125620A (ru) * 2006-12-07 2011-01-20 Новартис АГ (CH) Органические соединения

Also Published As

Publication number Publication date
IL231079A (en) 2015-02-26
KR20090038479A (ko) 2009-04-20
SMP200900013B (it) 2010-01-19
PE20110218A1 (es) 2011-04-01
IL231079A0 (en) 2014-03-31
WO2008016893A1 (en) 2008-02-07
US8546336B2 (en) 2013-10-01
EP2537850A1 (en) 2012-12-26
PL2051990T3 (pl) 2013-07-31
IL196596A0 (en) 2009-11-18
HN2009000214A (es) 2011-10-11
AU2007281230A1 (en) 2008-02-07
MA30652B1 (fr) 2009-08-03
ME00585A (en) 2011-12-20
HRP20130373T1 (en) 2013-05-31
IL196596A (en) 2014-09-30
UA95485C2 (uk) 2011-08-10
CU23866B1 (es) 2013-03-27
US20140004101A1 (en) 2014-01-02
CU20090017A7 (es) 2011-03-21
EP2051990A1 (en) 2009-04-29
ZA200900371B (en) 2009-12-30
BRPI0714803B8 (pt) 2021-05-25
PE20110217A1 (es) 2011-04-01
GT200900019A (es) 2010-06-01
EP2537846A1 (en) 2012-12-26
TN2009000034A1 (en) 2010-08-19
CR10567A (es) 2009-02-18
MY150460A (en) 2014-01-30
GT200900019AA (es) 2015-11-24
SV2009003160A (es) 2010-04-13
KR101245945B1 (ko) 2013-03-22
KR20110030667A (ko) 2011-03-23
NI200900081A (es) 2010-01-07
SMAP200900013A (it) 2009-05-11
AR062159A1 (es) 2008-10-22
CA2658525C (en) 2013-02-19
CU24004B1 (es) 2014-06-27
EA200900227A1 (ru) 2009-08-28
NI200900008A (es) 2010-01-07
CN101511860A (zh) 2009-08-19
CU20110027A7 (es) 2011-12-28
PE20110220A1 (es) 2011-04-11
AU2007281230B2 (en) 2011-09-08
EA021671B1 (ru) 2015-08-31
PA8740901A1 (es) 2009-04-23
HK1176613A1 (en) 2013-08-02
SI2051990T1 (sl) 2013-06-28
US20130005663A1 (en) 2013-01-03
DOP2013000084A (es) 2013-06-15
TWI408133B (zh) 2013-09-11
AR112816A2 (es) 2019-12-18
CR20140555A (es) 2015-01-14
CN102558165B (zh) 2014-08-13
NZ574393A (en) 2012-03-30
CL2007002234A1 (es) 2008-06-13
CA2658525A1 (en) 2008-02-07
HK1127616A1 (en) 2009-10-02
EP2537846B1 (en) 2015-09-16
CN102558165A (zh) 2012-07-11
EA201401247A1 (ru) 2015-07-30
DK2051990T3 (da) 2013-05-13
AR110313A2 (es) 2019-03-13
BRPI0714803A2 (pt) 2013-05-21
ME00585B (me) 2011-12-20
KR101087878B1 (ko) 2011-11-30
MX2009001212A (es) 2009-02-11
NO20090878L (no) 2009-04-27
US20110065726A1 (en) 2011-03-17
IL236883A0 (en) 2015-03-31
GEP20115251B (en) 2011-07-11
PE20110224A1 (es) 2011-04-05
TW200815399A (en) 2008-04-01
ES2405947T3 (es) 2013-06-04
US8552003B2 (en) 2013-10-08
PT2051990E (pt) 2013-05-10
JP2009545613A (ja) 2009-12-24
ES2559042T3 (es) 2016-02-10
JP4875749B2 (ja) 2012-02-15
NO342230B1 (no) 2018-04-23
BRPI0714803B1 (pt) 2021-03-09
JO2848B1 (en) 2014-09-15
CN101511860B (zh) 2013-05-01
EP2051990B1 (en) 2013-02-06

Similar Documents

Publication Publication Date Title
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
PE20081532A1 (es) Compuestos novedosos
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
PE20210372A1 (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
AR104566A2 (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
CL2009000323A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
CL2009000324A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
PE20110308A1 (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
PE20070427A1 (es) Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
HN2011000699A (es) El compuesto (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico en forma libre o de sal y composiciones y composicion farmaceutica que lo contiene.
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
RU2015112192A (ru) 2-оксо-2,3,4,5-тетрагидро-1н-бензо[b]диазепины и их применение при лечении рака
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20091486A1 (es) Derivado de pirrolopirimidina como inhibidor de la enzima pi3k
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
PE20090875A1 (es) Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.

Legal Events

Date Code Title Description
FG Grant, registration